Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Employment agrmnt
Auditor change
Director comp.
Appointed director
INVIVO THERAPEUTICS HOLDINGS CORP. (NVIV) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
05/12/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/25/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
04/24/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
03/09/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "InVivo Therapeutics Announces Topline Data from Pivotal INSPIRE 2.0 Study in Acute Spinal Cord Injury"
03/01/2023 10-K Annual Report for the period ended December 31, 2022
02/14/2023 SC 13G ARMISTICE CAPITAL, LLC reports a 10% stake in InVivo Therapeutics Holdings Corp.
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
11/22/2022 EFFECT Form EFFECT - Notice of Effectiveness:
11/21/2022 4 CHRISTOPHER RICHARD (CFO) has filed a Form 4 on INVIVO THERAPEUTICS HOLDINGS CORP.
Txns: Granted 20,800 options to buy @ $2.5, valued at $52k
11/21/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/21/2022 4 ROSENTHAL BOB (Director) has filed a Form 4 on INVIVO THERAPEUTICS HOLDINGS CORP.
Txns: Granted 4,200 options to buy @ $2.5, valued at $10.5k
11/21/2022 4 ROBERTS RICHARD JOHN (Director) has filed a Form 4 on INVIVO THERAPEUTICS HOLDINGS CORP.
Txns: Granted 4,200 options to buy @ $2.5, valued at $10.5k
11/21/2022 4 Hamel Heather (Chief Legal Officer and GC) has filed a Form 4 on INVIVO THERAPEUTICS HOLDINGS CORP.
Txns: Granted 13,400 options to buy @ $2.5, valued at $33.5k
11/21/2022 4 MARSHAK DANIEL R (Director) has filed a Form 4 on INVIVO THERAPEUTICS HOLDINGS CORP.
Txns: Granted 4,200 options to buy @ $2.5, valued at $10.5k
11/21/2022 4 MERRIFIELD C ANN (Director) has filed a Form 4 on INVIVO THERAPEUTICS HOLDINGS CORP.
Txns: Granted 4,200 options to buy @ $2.5, valued at $10.5k
11/21/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/21/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
11/18/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amendment to Employment Agreement, by and between InVivo Therapeutics Holdings Corp. and Richard Christopher"
11/08/2022 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
11/07/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
11/07/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/14/2022 D Form D - Notice of Exempt Offering of Securities:
10/11/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
10/11/2022 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "PRE-FUNDED COMMON STOCK PURCHASE WARRANT InVivo Therapeutics Holdings Corp. Warrant Shares: _______ Issue Date:______, 2022 Initial Exercise Date: _______, 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above and until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from InVivo Therapeutics Holdings Corp., a Nevada corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 .    &#...",
"PRE-FUNDED COMMON STOCK PURCHASE WARRANT InVivo Therapeutics Holdings Corp. Warrant Shares: _______ Issue Date:______, 2022 Initial Exercise Date: _______, 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above and until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from InVivo Therapeutics Holdings Corp., a Nevada corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 .    &#...",
"PREFERRED INVESTMENT OPTION InVivo Therapeutics Holdings Corp. Preferred Investment Option Shares: ______ Issue Date: ______, 2022 Initial Exercise Date: _______, 2022 THIS PREFERRED INVESTMENT OPTION certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above and on or prior to 5:00 p.m. on _____, 20__ 1 but not thereafter, to subscribe for and purchase from InVivo Therapeutics Holdings Corp., a Nevada corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Preferred Investment Option shall be equal to the Exercise Price, as defined in Section 2. Section 1 .  ...",
"PLACEMENT AGENT PREFERRED INVESTMENT OPTION InVivo Therapeutics Holdings Corp. Preferred Investment Option Shares: ______ Issue Date: October 11, 2022 Initial Exercise Date: October 11, 2022 THIS PLACEMENT AGENT PREFERRED INVESTMENT OPTION certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above and on or prior to 5:00 p.m. on October 7, 2027 but not thereafter, to subscribe for and purchase from InVivo Therapeutics Holdings Corp., a Nevada corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Preferred Investment Option shall be equal to the Exercise Price, as define...",
"Re: Registration Statement on Form S-3",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of October 7, 2022, between InVivo Therapeutics Holdings Corp., a Nevada corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act as to the Shares and the Pre-Funded Warrants and an exemption from the registration requirements of Section 5 of the Securities Act contained in Section 4 thereof and/or Regulation D thereunder as to the Preferred Investment Options and the Warrant Amendment, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Comp...",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of October 7, 2022, between InVivo Therapeutics Holdings Corp., a Nevada corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4 of the Securities Act , and Rule 506 promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company...",
"REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement is made and entered into as of October 7, 2022, between InVivo Therapeutics Holdings Corp., a Nevada corporation , and each of the several purchasers signatory hereto . This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and each Purchaser . The Company and each Purchaser hereby agree as follows: 1.              Definitions . Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings: “ Advice ” shall ha...",
"InVivo Therapeutics Announces $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules CAMBRIDGE, Mass.---- InVivo Therapeutics Holdings Corp. , a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the sale and issuance of 523,810 shares of the Company’ s common stock , in a registered direct offering priced at-the-market under Nasdaq rules. Concurrently with the registered direct offering, the Company entered into a definitive agreement with the investor in the registered direct offering for the sale and issuance of 1,190,476 shares of common stock in a..."
10/11/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
09/13/2022 8-K Material Modifications to Rights of Security Holders, Departure of Directors or Certain Officers; Election of Directors; Appo...
Docs: "Certificate of Amendment to the Articles of Incorporation filed with the Nevada Secretary of State",
"Certificate of Amendment to the Articles of Incorporation filed with the Nevada Secretary of State"
08/18/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
08/11/2022 PRER14A Form PRER14A - Preliminary Proxy Soliciting materials:
08/08/2022 10-Q Quarterly Report for the period ended June 30, 2022
07/25/2022 PRER14A Form PRER14A - Preliminary Proxy Soliciting materials:
07/18/2022 3 Form 3 - Initial statement of beneficial ownership of securities:
07/12/2022 8-K Quarterly results
07/08/2022 PRE 14A Form PRE 14A - Other preliminary proxy statements:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy